The COO of GeneFrontier Corporation since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. Earned a Ph.D. in cell-free protein synthesis from Tokyo Institute of Technology in 2000, and played a key role in the establishment of GeneFrontier in 2003, leveraging his deep expertise in cell-free protein synthesis following experience in life science venture capital.
PUREfrex® is a fully reconstituted, cell‑free protein expression system enabling rapid, high‑throughput antibody engineering. It efficiently produces scFv, Fab, and IgG, and supports robust ribosome display (PUREfrexRD) for screening highly diverse libraries. Combined with AI/ML workflows, PUREfrex® accelerates discovery of next‑generation antibodies and cyclic peptide modalities with enhanced precision, flexibility, and scalability for biologics R&D.